ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GTX Genetix Grp

84.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genetix Grp LSE:GTX London Ordinary Share GB0001276863
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 84.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Genetix Grp Share Discussion Threads

Showing 126 to 149 of 175 messages
Chat Pages: 7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
18/11/2005
23:56
i'm back in after a long time out of these! Anyone else around?
jpuff
23/3/2005
11:50
dont wast your money
dpd
03/3/2005
13:23
Just had a few days away, and its nice to come back to a little positive direction.

I missed the results the other day



Which after a quick glance look very reasonable, and wish them the best in gaining a decent slice of.... 'Our key priority in 2005 is to concentrate activity on the potentially significant markets within cell biology and penetrate these as quickly as possible'


Also still a quite board, with a price that looks far from overstretched.

games
03/3/2005
10:36
bought a few today.Volumes look encouraging
kennerland
03/3/2005
08:53
like it even more - up 7% today
25october1969
02/3/2005
16:32
And at 4.25-4.30 it suddenly shoots up 1.5 and on line can sell 50,000 and only buy 2500..............I have no idea what it is but I like it
25october1969
02/3/2005
15:56
ANyone any idea what is happening with the volume today, almost 3 million so far today and no price movement. One definate X of 500,000 but at least 1.5m buys
25october1969
15/2/2005
10:21
Hi Roy,

Ref earlier post: Its the Genetix AliQuot product, and BMS (Bristol-Myers Squibb) who were contemplating using the product. (arond mid Jan)

As for the cash balance, sure its nice to have a pile, but imo its too high a percentage of the mkt-cap at the moment, and will more than likely act as a dampner till profits/eps are somewhat higher.

games
15/2/2005
10:01
HI games

Looks an interesting share and I see the cash balance very much as a positive. The next set of results are obviously important as much for the outlook as for the figures have bought in over the last few days - before todays price rise I am pleased to say

cheers

Roy

25october1969
14/2/2005
21:57
Bit of a sleepy thread this one, is anyone lurking out there with an opinion on these.

£34m mkt cap

£21.7m cash, approx £25m nav (without the intangibles)

H1 sales (June04) of £6.7m (+38%)

Adjusted EPS (excluding goodwill) up 51%; basic EPS up 100%

downside: pre-tax profit of £0.4 million up 78%, which would be fine with a mkt cap around £12m especially if the finals on March 1st come in good, but
the large amount of cash will be a dampner.

New product (clonepix. FL) announced very recently, which has gained some interest from
the majors, and i did come across a snip where a large company had the product short-listed, that has yet has not being mentioned by the company.

veiws anyone?

games
21/11/2003
11:35
Ultrasis (ULT) a potential 10 to 20 bagger short-term imo.
qazwsx123
05/11/2003
13:45
pfb5

I seek not attention, I seek investors!
Good to have some company.

p.s. I don't understand my last two posts either! ;)

mad4it
05/11/2003
13:36
mad41T:

I don't understand your last two posts, but if you're seeking attention, you're not the only one who's watching - I own some of these too!

pfb5
03/11/2003
16:43
" I wandered lonely as a cloud. "
mad4it
29/10/2003
15:21
lovecustard - 14 May'03 - 08:36 - 5 of 6

last mm on offer
........................................

He's right you know! lol!

mad4it
29/10/2003
13:30
Anyone watching these ? I bought a few at 48p and 60p.

This looks like a good potential recovery story to me. A profitable company, with Approx 29p in cash, supplying state of the art equipment to the biotech industry. Recent director purchase of 50k at 55p and it's good to see the options issued to the new COO at 51.5p are performance related.

I remember when GTX floated, their products were considered second to none. We are seeing a lot of growth in the biotech areas where they are supplying products and their products are still seen as a must have by the big Pharma companies (see below). Worth a punt I reckon. Here's the most recent, relevant info:

29/07/03:
LONDON (AFX) - Genetix Group PLC said sales fell to 4.9 mln stg from 6.3 mln
stg in a continuing difficult trading environment.
For the six months to June 30, pre-tax profit fell to 0.2 million from 1 mln
stg in 2002.
It said conditions were challenging throughout the first six months of 2003.
Difficulties for the biotechnology sector in raising funds, cutbacks and delays
in academic grants, and pressure on pharmaceutical companies to orientate their
R&D towards late-stage products have put pressure on supplier companies such as
Genetix, it said.
But despite these "tough conditions", Genetix remains profitable overall and
financially strong with 21.4 mln stg of cash in the bank and an innovative
pipeline of new products to generate future revenue, it said.
Looking ahead, it said it remains confident in the company's ability to
increase its market share as well as the opportunities to enter new markets.
But in view of the continuing uncertain trading environment, the company
remain cautious about prospects for 2003, although it anticipates maintaining a
strong cash position of over 20 mln stg throughout the year.
"We are encouraged by recent signs of a return of investor confidence in the
biotech sector on the back of promising clinical data and product approvals,
which underline the long-term promise of the industry," it said.

.............................................................................

RNS Number:5130O
Genetix Group PLC
11 August 2003

Genetix launches the aliQuot liquid handler
Pre-launch orders placed by two of the top three major pharmaceutical companies


Boston, USA, 11 August 2003 - Genetix Group plc (LSE: GTX), the genomics and
proteomics technology group, today announces the launch of the aliQuot, an
automated solution for the low volume dispensing of reagents, chemicals, cells,
beads, reaction mixes and other media, at the Drug Discovery Technology
conference in Boston, USA.

The aliQuot, a desktop machine, uses a proprietary fast pressure-timing dispense
mechanism to fill a 1536-well plate with one microlitre in under 30 seconds. The
level of accuracy (well-to-well CV of approximately 5%) is unsurpassed by any
other instrument in its price bracket. The major markets for this product will
be drug discovery, forensics, genetic screening, genomics research and high
throughput screening.

Low volume dispensing is economically beneficial to pharmaceutical companies
when testing compounds with reagents which can cost thousands of dollars per
millilitre. Using smaller volumes in these assays enables a greater number of
tests to be carried out, or the same number of tests at less cost. Another
feature of the aliQuot which reduces the cost of assays is a backfilling
function which allows unused compound or reagent remaining in the dispensing
pipes to be flushed back into the reservoir bottle for future use.

Future developments are likely to include the simultaneous dispensing of up to
eight reagents.

Julian Burke PhD, Chief Scientific Officer of Genetix, commented:

"The aliQuot makes small volume dispensing accessible to laboratories previously
unable to conduct assays on this scale because of budget or space constraints,
it also offers a more economical solution to those larger companies already
conducting tests on this level. Building on skills acquired during the
development of the Qfill2 liquid handler, Genetix is able to offer this small
volume capability at excellent speed and accuracy to it customers. Multiple
pre-launch orders have already been received by two of the three leading
pharmaceutical companies."

mad4it
12/8/2003
09:48
It's on it's way back down again now, think I have missed the boat to day trade this one.
speny
12/8/2003
08:53
This share will close at 90p today
tcpipman
12/8/2003
08:33
Yes me, bought pre-market yesterday.Last line in statement was most important:-"Multiple pre-launch orders have already been received by two of the leading pharmaceutical companies"
steadyeddy
12/8/2003
08:30
in at 43p mate!
tonyleongson
12/8/2003
07:41
Up 19% today - days biggest gainer. Is anyone watching?
ok,yah
11/8/2003
13:43
Yep, cash rich company that is profit making. Twenty one million quid in the bank without cash burn.

Looks like a fairly low risk entry into a rapidly growing area - Gene Research.

Todays announcement - two products launched with orders already in the bag:-

Genetix Group PLC, which makes equipment for research into
human and plant genomics, said it has launched ClonePix, a new instrument for
mammalian cell colony picking, which the company says is the first step in the
production and selection of monoclonal antibodies.
"Monoclonal antibody production is an increasingly important area of focus
for biotechnology companies," Genetix said.
"Around 25 pct of biopharmaceutical drugs currently in Phase II trials are
based on monoclonal antibodies."
Genetix launched the product at the Drug Discovery Technology conference in
Boston in the US.
Genetix also said it launched aliQuot, an automated solution for the low
volume dispensing of reagents, chemicals, cells, beads, reaction mixes and other
media.
The major markets for this product will be drug discovery, forensics,
genetic screening, genomics research and high throughput screening, it said.
bam

ok,yah
08/8/2003
08:42
8 August 2003,
Alizyme (AZM):

Superb announcement from Alizyme today regarding out-licensing deal with Takeda, the largest pharmaceutical company in Japan, for Japanese rights to ATL-962 for the treatment of obesity and all related diseases.

* Exclusive rights for Japan.

* Total agreement worth up to US$42 million:
..........US$2 million payable immediately
..........US$40 million payable on future milestones/events
..........US $42 total (i.e. between now and ATL-962 reaching the market)

* Double digit royalties on future sales by Takeda in Japan.

* All development costs in Japan paid by Takeda.

qazwsx123
23/5/2003
07:48
westex

Click on 'Fundamentals' and it looks to me like there's 72.7m shares in issue and £20.87m in the bank as at 31/12/02, so isn't that 28.7p per share?

CEO, Chairman, Directors & cronies, employees, already hold more than two-thirds of the shares in issue.

MBO unlikely, basically they already control it?

pfb5
Chat Pages: 7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock